ATE390140T1 - Arzneimittel, umfassend eine kombination aus metformin und glibenclamide - Google Patents

Arzneimittel, umfassend eine kombination aus metformin und glibenclamide

Info

Publication number
ATE390140T1
ATE390140T1 AT00972122T AT00972122T ATE390140T1 AT E390140 T1 ATE390140 T1 AT E390140T1 AT 00972122 T AT00972122 T AT 00972122T AT 00972122 T AT00972122 T AT 00972122T AT E390140 T1 ATE390140 T1 AT E390140T1
Authority
AT
Austria
Prior art keywords
glibenclamide
metformin
combination
medicinal products
medicinal
Prior art date
Application number
AT00972122T
Other languages
German (de)
English (en)
Inventor
Beth PIPER
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE390140T1 publication Critical patent/ATE390140T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00972122T 1999-11-03 2000-10-13 Arzneimittel, umfassend eine kombination aus metformin und glibenclamide ATE390140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
ATE390140T1 true ATE390140T1 (de) 2008-04-15

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00972122T ATE390140T1 (de) 1999-11-03 2000-10-13 Arzneimittel, umfassend eine kombination aus metformin und glibenclamide

Country Status (23)

Country Link
EP (1) EP1229918B1 (enExample)
JP (1) JP5183844B2 (enExample)
KR (1) KR20070089259A (enExample)
CN (1) CN1450902A (enExample)
AR (1) AR026356A1 (enExample)
AT (1) ATE390140T1 (enExample)
AU (1) AU780106B2 (enExample)
BR (1) BR0015294A (enExample)
CA (1) CA2389928C (enExample)
EE (1) EE05260B1 (enExample)
HU (1) HU229352B1 (enExample)
IL (1) IL149139A0 (enExample)
LT (1) LT5058B (enExample)
LV (1) LV12910B (enExample)
MX (1) MXPA02004282A (enExample)
NO (1) NO330026B1 (enExample)
NZ (1) NZ518278A (enExample)
PL (1) PL199278B1 (enExample)
RU (1) RU2275915C2 (enExample)
SK (1) SK287810B6 (enExample)
TW (1) TWI280125B (enExample)
UY (1) UY26424A1 (enExample)
WO (1) WO2001032157A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
RU2387445C2 (ru) * 2004-05-03 2010-04-27 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Материалы и способы модуляции метаболизма
TWI421102B (zh) 2007-07-19 2014-01-01 Takeda Pharmaceutical 固態製劑
WO2009035969A1 (en) 2007-09-10 2009-03-19 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of sglt
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PL3417871T3 (pl) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
EP2670427A1 (en) * 2011-02-02 2013-12-11 Sanofi-Aventis Deutschland GmbH Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
EP1787646A3 (en) 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
CA2389928C (en) 2010-03-23
LV12910B (en) 2003-05-20
EP1229918A2 (en) 2002-08-14
SK287810B6 (sk) 2011-10-04
RU2002114820A (ru) 2004-03-10
HUP0300218A2 (hu) 2003-06-28
SK5002002A3 (en) 2004-05-04
CA2389928A1 (en) 2001-05-10
LT5058B (lt) 2003-09-25
AU780106B2 (en) 2005-03-03
HU229352B1 (en) 2013-11-28
NO330026B1 (no) 2011-02-07
EE05260B1 (et) 2010-02-15
MXPA02004282A (es) 2003-02-17
JP5183844B2 (ja) 2013-04-17
UY26424A1 (es) 2001-05-31
WO2001032157A3 (en) 2002-01-24
RU2275915C2 (ru) 2006-05-10
AU1082601A (en) 2001-05-14
EE200200242A (et) 2003-12-15
NO20022087L (no) 2002-06-24
KR20070089259A (ko) 2007-08-30
NZ518278A (en) 2004-10-29
HUP0300218A3 (en) 2006-02-28
BR0015294A (pt) 2003-07-15
PL364885A1 (en) 2004-12-27
NO20022087D0 (no) 2002-05-02
CN1450902A (zh) 2003-10-22
IL149139A0 (en) 2002-11-10
WO2001032157A2 (en) 2001-05-10
JP2003519621A (ja) 2003-06-24
TWI280125B (en) 2007-05-01
PL199278B1 (pl) 2008-09-30
AR026356A1 (es) 2003-02-05
EP1229918B1 (en) 2008-03-26
LT2002063A (en) 2003-06-25

Similar Documents

Publication Publication Date Title
ATE390140T1 (de) Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
DE60038455D1 (de) Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
ATE247489T1 (de) Arzneimittel enthaltend einen basischen wirkstoff,ein cyclodextrin, ein polymer und eine saure
DE69907698D1 (de) Azetidinderivate, deren herstellung und sie enthaltende arzneimittel
DE50313653D1 (de) Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
NO20042713L (no) Farmasoytiske preparater omfattende metformin og glibenklamid for behandling av type ll diabetes mellitus
EE05292B1 (et) 6-alkenl-, 6-alknl- ja 6-epoksepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
FI19991852L (fi) Uusi monikerroksinen materiaali, joka käsittää vaikuttavan ainesosan, ja sen valmistus
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
DE59810448D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
SI1572707T1 (sl) Novi aromatski fluorglikozidni derivati, farmacevtski proizvodi, ki vsebujejo te spojine, in njihova uporaba
DE60016602D1 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
ATE250418T1 (de) Tabletten enthaltend eine kombination von glibenclamid und metformin
ATE202472T1 (de) Arzneimittel enthaltend oxaliplatin
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DE60037269D1 (de) Gemischte metal-alkoxid-verbindungen und aus diesen hergestellte polymerisationskatalysatoren
DE69519368D1 (de) Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
IL149209A0 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
ATE337321T1 (de) Cabapenemderivate, ihre anwendung und ihre zwischenprodukte
DE69918433D1 (de) C11-oxymyl- and hydroxylamino-prostaglandine und ihre anwendung als arzneimittel
HUP0300295A3 (en) Substituted benzamide derivatives, pharmaceutical compositions containing them and their use
DE69709349D1 (de) Arzneimittel bestehend aus diclofenac
DE60144456D1 (de) DibenzoÄb,fÜazepin-Derivate und ihre Herstellung
DE69512715D1 (de) Aconitin ähnliche verbindung und antipyretisches, analgetisches und entzündungshemmendes mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties